Introduction L’omalizumab, anticorps monoclonal anti-IgE est un traitement de l’asthme allergique, sévère non contrôlé.

Observation Il s’agit d’un asthme allergique, sévère chez un insuffisant rénal dialysé, en attente de transplantation rénale. L’asthme est non contrôlé et la fonction respiratoire est altérée. Il va pouvoir bénéficier d’un traitement par anticorps anti-IgE, l’améliorant rapidement et permettant la transplantation dans de bonnes conditions.

Conclusion Les anticorps anti-IgE améliorent les asthmes allergiques jusqu’ici instables et sévères, permettant à ce patient d’être transplanté sans complication respiratoire.

Introduction Omalizumab, a monoclonal antibody to IgE, is a possible treatment for severe, uncontrolled allergic asthma.

Case report A severe asthmatic patient with renal insufficiency and on dialysis was awaiting transplantation. The asthma was uncontrolled with poor respiratory function. He received anti IgE treatment with omazilumab with immediate clinical improvement and his renal transplant was performed satisfactorily.

Conclusion Anti-IgE treatment can improve severe, uncontrolled allergic asthmatic patients allowing, in this case, transplantation without further respiratory problems.